---
title: "Descartes-08 in Generalized myasthenia gravis: Cost-effectiveness evidence"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Cost-effectiveness evidence. Topics: ICER evaluation of eculizumab and efgartigimod: model framing and base-case results, ICER health benefit price benchmarks and budget impact for eculizumab and efgartigimod, Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG, Costs and cost-effectiveness of myasthenia gravis treatments across 31 articles, and 27 further topics. 32 evidence topics quoted from 31 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics/cost-effectiveness"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

- Descartes-08 price and revenue: the report holds no announced price for Descartes-08, and the company states that it has no products approved for sale and has not generated any product sales. An analyst page (2024) states that U.S. revenue for Descartes-08 is expected to reach an annual total of $201 mn by 2039 based on GlobalData's Expiry Model. A November 2026 company presentation describes a potential “$1B+ market opportunity for Descartes-08 in the US” and cites “Company internal projections, inclusive of opportunity to retreat patients”.
- Comparator acquisition costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart ($15.79/mg; 2 or 3 vials per dose, weight based) as of September 30, 2025, and of $16,410.23 per vial ($16.28/mg) and $17,066.64 per syringe ($17.07/mg) of Vyvgart Hytrulo, 1 per dose, as of October 1, 2026; a Rystiggo list price of $3,155.37 per mL (AnalySource, December 2025), dosed in cycles of 1 weekly subcutaneous infusion for 6 weeks; a Zilbrysq list price printed as “$1,1164.21 per 23.0 mg syringe” (AnalySource, January 2026); an Imaavy list price of $12,480 per vial (2025); $6,523 per single-dose vial of Soliris, $5,870.70 per single-dose vial of the biosimilar Bkemv, and $4,566.00 per single dose of Epysqli (2025); and an Uplizna wholesale acquisition cost of $140,248.50 per dose (3 vials), given every six months after two loading doses (2025). Among 5,033 patients in the Optum database (mean body weight 86.6 kg), the annual cost of health-care-provider-administered gMG treatment was estimated at $223,272 to $648,960 depending on drug and body weight, up to $648,960 for patients weighing more than 80 kg. In Medicare drug claims for immune-mediated neurologic disorders, inebilizumab and eculizumab had the highest mean payment per claim in 2022 ($38 993.14).
- ICER 2021 evaluation of eculizumab and efgartigimod: over a 2-year time horizon from a health system perspective, the incremental cost-effectiveness ratio for eculizumab, at an estimated annual cost of $653,100, was $5,210,000 per QALY/evLYG, and efgartigimod was analyzed at a placeholder price of $418,400. The ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million for efgartigimod, and in probabilistic sensitivity analyses neither drug reached cost-effectiveness at $150,000 per QALY/evLYG. Health benefit price benchmarks were $13,200 to $19,400 for eculizumab (97%-98% discount from the Federal Supply Schedule price) and $18,300 to $28,400 for efgartigimod, and 8.8% of the eligible population could be treated with efgartigimod at the placeholder price without passing the budget impact threshold.
- Other cost-effectiveness analyses: a lifetime Markov model estimated $3,338,000/QALY gained for eculizumab and $1,987,000/QALY gained for efgartigimod compared with conventional therapy, $3,310,000 and $1,959,000 after indirect costs were applied in a modified societal perspective, with discounts of 93.01% and 88.34% needed for cost-effectiveness. A study that included 31 articles found considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. A network meta-analysis of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan using 2026 U.S. drug and administration costs found the lowest cost per improved outcome for efgartigimod IV across all QMG and MG-ADL thresholds. From the Canadian publicly funded healthcare system perspective, efgartigimod dominated chronic immunoglobulins (3.45 incremental QALYs and cost savings of $257,020 over a lifetime). From a UK NHS and Personal Social Services perspective, thymectomy plus prednisolone dominated prednisolone alone (0.52 QALYs gained and £13 014 saved per patient). The cost per MG-ADL improvement with IVIg was estimated at 7000-17,000 Japanese yen, lower than that for molecular targeted drugs.
- CAR-T cell therapy costs: a single CAR T-cell infusion was described as approaching USD 500,000, and in a simple model the cumulative costs of systemic lupus erythematosus crossed that reference cost in approximately seven to eight years for very severe disease, 11 years for high disease activity, and 20 years for moderate disease activity. Among 8 patients with systemic lupus erythematosus followed for more than 2 years after CAR T cell therapy, annual direct healthcare costs in the German healthcare service fell from €29,672/year (US $34,353/year) to €3094/year ($3582/year). Among 271 commercially insured patients treated for B-cell lymphoma, median total costs were $608 100, the median cost of CAR-T products was $402 500, and 8.5% had total costs exceeding $1 million. Among 508 patients in a health plan claims database, mean total 30-day costs after infusion were $643,902 in the outpatient cohort and $691,771 in the inpatient cohort. The estimated total cost of care associated with CAR T-cell administration was $454 611 in academic inpatient hospitals and $421 624 in nonacademic specialty oncology networks. Costs of cilta-cel therapy excluding acquisition totaled US$160,933 over 12 months, including $18,268 in pre-infusion costs (apheresis, bridging therapy, and conditioning therapy), against a 2022 wholesale acquisition cost of $465,000. ICER's 2021 multiple myeloma assessment estimated $319,000 per QALY for ide-cel at its wholesale acquisition cost of $419,500 and a health benefit price benchmark of $192,000 to $265,000 per dose.
- CAR-T payment: across 391 Medicare CAR-T claims, 79% were administered in the inpatient setting, and the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. An inpatient case is paid through the claim's DRG, with the product included in a single payment for the stay, and a solely outpatient case is paid under the Outpatient Prospective Payment System at Average Sales Price plus 6%. In the FY 2027 final rule, CMS estimated average costs of $64,963 for clinical trial cases and $410,125 for nonclinical trial cases assigned to MS-DRG 018, and a commenter stated that the MS-DRG 018 base payment rate remains insufficient to cover the costs of CAR T-cell and other cellular immunotherapies.
- Eligible population inputs: ICER's 2021 budget impact model used 46,870 U.S. patients with gMG, assumed 100% diagnosis and 20% annual initiation (9,374 additional patients per year), and set initial market shares of 2.27% for eculizumab and 97.73% for conventional therapies. A November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020. Treatment-refractory gMG prevalence estimates range from 5% to 15%; among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first (n = 7986) and fifth (n = 3340) treatment episodes.

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm); [Pharmaceutical Technology Descartes-08 net present value page (2024)](https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-net-present-value/); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456); [argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_WAC_Disclosure_for_Colorado_HCPs.pdf); [argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_Hytrulo_WAC_Disclosure_for_Colorado_HCPs.pdf); [UCB RYSTIGGO pricing information (2025)](https://www.ucb-usa.com/Sustainability/Affordability/RYSTIGGO-Pricing-Info); [UCB ZILBRYSQ pricing information (2026)](https://www.ucb-usa.com/Sustainability/Affordability/ZILBRYSQ-Pricing-Info); [pharmaphorum Imaavy approval article (2025)](https://pharmaphorum.com/news/jjs-swiss-army-knife-drug-gets-first-fda-approval); [Managed Healthcare Executive eculizumab biosimilars article (2025)](https://www.managedhealthcareexecutive.com/view/bkemv-and-epysqli-two-biosimilars-of-soliris-are-now-available); [Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025)](https://www.managedhealthcareexecutive.com/view/fda-approves-uplizna-for-chronic-inflammatory-condition-igg4-rd); [Tse et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41422493/); [Wong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12538365/); [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/); [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf); [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/); [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/); [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/); [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/); [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/); [Suzuki et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42275909/); [Kumar and Kim (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13155473/); [Ribeiro et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40953960/); [Di et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/); [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12577723/); [Lyman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7136832/); [Jagannath et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10260711/); [ICER multiple myeloma final evidence report (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Unredacted_112222.pdf); [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11263250/); [Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026)](https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and); [Harris et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447171/); [Grover et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42839213/)

<a id="topic-4.1-2"></a>

### ICER evaluation of eculizumab and efgartigimod: model framing and base-case results

> “The analyses were framed to evaluate results over a 2-year time horizon, taking a health system perspective.”
> “However, despite the large impact of changing these inputs on the results, the incremental cost-effectiveness ratio was never less than $3.8 million per QALY/evLYG for eculizumab and $1.7 million per QALY/evLYG for efgartigimod. In probabilistic sensitivity analyses, neither drug was ever found to reach cost-effectiveness at the $150,000 per QALY/evLYG threshold.”

Source: [Tice et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373007/)

<a id="topic-4.1-3"></a>

### ICER health benefit price benchmarks and budget impact for eculizumab and efgartigimod

> “The HBPB range for eculizumab was estimated to be $13,200 to $19,400 (97%-98% discount from the Federal Supply Schedule [FSS] price). For efgartigimod, the HBPB range was estimated to be $18,300 to $28,400 (discounts not presented due to placeholder price) (Table ES2).”
> “The HBPB for a drug is defined as the drug price range that would achieve incremental cost-effectiveness ratios between $100,000 and $150,000 per QALY gained or per evLYG.”
> “In accordance with Figure 7.1, the percentage of the eligible population that can be treated with efgartigimod without passing the updated potential budget impact threshold is 8.8% at placeholder price ($418,000* per year).”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-4.1-4"></a>

### Lifetime U.S. cost-effectiveness of eculizumab and efgartigimod in AChR antibody-positive gMG

> “A Markov model with 4 health states was developed, evaluating costs and utility with a 4-week cycle length and lifetime time horizon from a health care system perspective and a modified societal perspective including productivity losses from patients and caregiver burden.”
> “Among the corresponding populations, lifetime costs and QALYs, respectively, for eculizumab were $5,515,000 and 11.85, and for conventional therapy, $308,000 and 10.29, resulting in an ICER of $3,338,000/QALY gained. For efgartigimod, lifetime costs and QALYs, respectively, were $6,773,000 and 13.22, and for conventional therapy, $322,000 and 9.98, yielding an ICER of $1,987,000/QALY gained.”
> “After applying indirect costs in a modified societal perspective, the ICERs were reduced to $3,310,000/QALY gained for eculizumab and $1,959,000/QALY gained for efgartigimod.”
> “To be considered cost-effective, eculizumab would need to be discounted by 93.01% and efgartigimod by 88.34% of the price that was used in the model’s base case.”

Source: [Lien et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144987/)

<a id="topic-4.1-5"></a>

### Costs and cost-effectiveness of myasthenia gravis treatments across 31 articles

> “The study included 31 articles showing a considerable variability in the costs and cost-effectiveness of MG treatments across regions, therapies, and health care settings. Traditional therapies such as plasma exchange (PLEX) and intravenous immunoglobulin (IVIg) differ notably in cost, with PLEX generally being less expensive. Newer clinically effective treatments such as efgartigimod and eculizumab raise concerns about their economic sustainability, whereas rituximab might be a more affordable alternative in certain contexts.”

Source: [Çipi et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12836010/)

<a id="topic-4.1-6"></a>

### Cost per improved outcome of approved biologics: network meta-analysis with 2026 U.S. costs

> “A de novo NMA was performed using data from Phase III placebo-controlled trials of efgartigimod IV, inebilizumab, nipocalimab, ravulizumab, rozanolixizumab, and zilucoplan, including recently approved therapies.”
> “Cost per improved outcome (CPIO) was calculated using NNTs and 2026 US drug/administration costs.”
> “Efgartigimod IV had the lowest CPIO across all QMG and MG-ADL thresholds, significantly lower than almost all other treatments (p < 0.05).”

Source: [Smith et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42495790/)

<a id="topic-4.1-7"></a>

### Canadian cost-utility analysis of efgartigimod compared with chronic immunoglobulin

> “The analysis was conducted from the perspective of the Canadian publicly funded healthcare system over a lifetime horizon.”
> “Over a lifetime horizon, efgartigimod and chronic immunoglobulins were predicted to have total discounted QALYs of 16.80 and 13.35 and total discounted costs of $1,913,294 and $2,170,315, respectively. Efgartigimod dominated chronic immunoglobulins with incremental QALYs of 3.45 and cost savings of $257,020.”

Source: [Siddiqi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41139802/)

<a id="topic-4.1-8"></a>

### Cost-effectiveness of thymectomy in nonthymomatous myasthenia gravis: United Kingdom

> “The model adopted a UK NHS and Personal Social Services perspective over a lifetime horizon.”
> “In the base-case analysis, thymectomy plus prednisolone dominated prednisolone alone, yielding higher health gains (14.63 QALYs vs 14.11 QALYs) and lower lifetime costs (£181 716 vs £194 730). This generated an incremental gain of 0.52 QALYs and a cost saving of £13 014 per patient.”
> “These findings support current clinical guidelines recommending thymectomy for eligible patients and establish it as the most relevant comparator in evaluations of future health technologies.”

Source: [Lord et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13077509/)

<a id="topic-4.1-9"></a>

### Cost per responder of intravenous immunoglobulin compared with molecular targeted drugs: Japan

> “The cost-effectiveness of IVIg and molecular targeted drugs was evaluated using cost per responder and cost per Myasthenia Gravis Activities of Daily Living (MG-ADL) improvement analyses.”
> “The cost per MG-ADL improvement was estimated at 7000-17,000 Japanese yen, which was substantially lower than that for molecular targeted drugs.”

Source: [Suzuki et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42275909/)

<a id="topic-4.1-10"></a>

### Direct healthcare costs before and after CD19 CAR-T cell therapy in systemic lupus erythematosus: Germany

> “Annual direct healthcare costs were analyzed based on inpatient admissions, emergency department visits, outpatient visits, and prescription drug costs in the German healthcare service.”
> “A preliminary analysis was conducted on 8 patients with SLE (7 female, 1 male; age range 19-38 years) who received CAR T cell therapy and who were followed for > 2 years.”
> “Additionally, CAR T cell therapy led to a substantial decrease in annual direct healthcare costs from €29,672/year (US $34,353/year) to €3094/year ($3582/year) after treatment.”

Source: [Ribeiro et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/40953960/)

<a id="topic-4.1-11"></a>

### Break-even analysis of a CAR-T cell therapy reference price against cumulative costs of systemic lupus erythematosus: United States

> “A single infusion of chimeric antigen receptor (CAR) T-cell therapy (CTCT) is currently expensive, approaching USD 500,000, but the lifetime costs of SLE, including medications, hospitalizations, travel, mental health effects, and lost income, may surpass this figure within years to over a decade, depending on disease severity.”
> “Costs for patients with very severe SLE cross the reference CTCT cost in approximately seven to eight years. Estimated breakeven timelines vary by severity level as follows: patients with high disease activity reach breakeven in approximately 11 years, and those with moderate disease activity in approximately 20 years. For mild or inactive SLE, CTCT is not cost-effective at current prices within a clinically meaningful timeframe.”
> “Looking forward, emerging strategies, such as off-the-shelf (allogeneic) CTCT, RNA delivery, or hospital-based manufacturing, could reduce CAR T manufacturing costs to USD 80,000 or below [22-24].”
> “We used a simple model to compare the financial burden of living with SLE to the cost of a single dose of CTCT. Our model did not account for all factors, such as inflation, regional cost differences, or changes in insurance coverage.”

Source: [Kumar and Kim (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13155473/)

<a id="topic-4.1-12"></a>

### Total cost of care around commercial CAR-T cell therapy for B-cell lymphoma: U.S. commercial claims, 2018 to 2021

> “Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%).”
> “Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521 500), with median costs below $25 000 in all other 28-day intervals.”
> “Our study also showed higher costs associated with inpatient CAR-T therapy compared with outpatient therapy delivery.”
> “The savings from outpatient delivery accounted for just a small proportion of total costs, however, because of the substantial cost of CAR-T products.”

Source: [Di et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/)

<a id="topic-4.1-13"></a>

### Thirty-day costs after CAR-T cell infusion by setting of care: U.S. commercial claims for diffuse large B-cell lymphoma, 2017 to 2024

> “A retrospective cohort study was conducted leveraging IQVIA PharMetrics Plus Health Plans Claims database between January 2017 and March 2024.”
> “There were 508 patients receiving CAR T infusion and meeting all selection criteria. 442 patients had CAR T administered in the inpatient setting, and 66 had it in the outpatient setting.”
> “Within 30 days following CAR T infusion, 48.5% of the outpatient cohort and 60.9% of patients receiving axi-cel in the outpatient setting had an inpatient stay, with lower rates of intensive care unit admissions (overall: 18.2% vs 43.9%; axi-cel: 39.1% vs 43.5%) and shorter median inpatient stays (overall: 9.0 vs 15.0 days; axi-cel: 11.0 vs 15.0 days) than the inpatient cohort. The mean total 30-day costs appeared lower in the outpatient cohort, overall ($643,902 vs $691,771) and for axi-cel ($695,904 vs $741,449).”

Source: [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12577723/)

<a id="topic-4.1-14"></a>

### Medicare costs and reimbursement of CAR-T cell therapy by setting of care: fee-for-service claims, 2021 to 2022

> “Among the total 391 CAR T claims assessed, most of the CAR T therapies were administered in the inpatient setting (79%) compared to outpatient (21%).”
> “CAR T therapy in the inpatient setting received an average Medicare cost of US$498,723”
> “while the average Medicare cost for outpatient CAR T claims was $414,393”
> “Despite the higher post-period cost, when looking at the CAR T procedure and pre- and post-periods as a single episode, beneficiaries receiving outpatient CAR T had less cost for the total episode of care ($587,908 vs. $529,188).”
> “When an OP case is admitted into the same hospital within 72 h, the CAR T infusion will be designated by CMS as IP and paid based on the claim's DRG (diagnosis-related grouping). DRG payment rates are set by CMS' Inpatient Prospective Payment System. In IP claims, the CAR T product is not reimbursed individually but rather it is part of a single payment for the entire IP stay. When a case is solely OP (without any IP admission within 72 h), the CAR T product is paid under CMS' Outpatient Prospective Payment System and is set to Average Sales Price (ASP) plus 6%.”

Source: [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11263250/)

<a id="topic-4.1-15"></a>

### Modeled cost of CAR-T cell therapy administration by site of care: academic inpatient hospital compared with nonacademic specialty oncology network

> “The estimated total cost of care associated with the administration of CAR T-cell therapy was $454 611 (95% CI, $452 466-$458 267) in the academic hospital inpatient setting compared with $421 624 (95% CI, $417 204-$422 325) in the nonacademic specialty oncology network setting, for a difference of $32 987. After excluding the CAR T-cell acquisition cost, hospitalization and office visit costs were $53 360 (65.3% of the total cost) in academic inpatient hospitals and $23 526 (48.4% of the total cost) in nonacademic specialty oncology networks.”

Source: [Lyman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7136832/)

<a id="topic-4.1-16"></a>

### Costs of CAR-T cell therapy beyond product acquisition, including apheresis: U.S. commercial perspective, multiple myeloma

> “The estimated per-patient average costs of cilta-cel CAR-T therapy administered exclusively in an inpatient setting, excluding cilta-cel therapy acquisition costs, totaled US$160,933 over a 12 month period. Costs assuming different proportions of inpatient/outpatient administration (85%/15% and 70%/30%) were US$158,095 and US$155,257, respectively.”
> “The cost of apheresis was sourced from the CMS 2021 Physician Fee Schedule, a publicly available database [10].”
> “Pre-infusion costs including apheresis, bridging therapy, and conditioning therapy totaled $18,268.”
> “Our estimated per-patient average costs of cilta-cel CAR-T therapy totaled $160,933, excluding the acquisition cost of cilta-cel, which had a 2022 wholesale acquisition cost of $465,000 [23].”

Source: [Jagannath et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10260711/)

<a id="topic-4.1-17"></a>

### ICER assessment of anti-BCMA CAR-T cell therapies in multiple myeloma: list price, health benefit price benchmarks, and budget impact

> “We used the list price for ide-cel and, in the absence of any available market projection or other data, assumed the same price for cilta-cel.”
> “Patients that discontinued the CAR-T treatment before receiving the CAR-T infusion were not charged the CAR-T costs.”
> “We arrive at a range of HBPB of approximately $192,000 - $265,000 for ide-cel, $230,000 - $312,000 for cilta-cel, and $8,300 - $9,500 for belantamab.”
> “The incremental cost-effectiveness ratio for ide-cel using the base case was $319,000 per QALY. ICER’s recommended health-benefit price benchmark (HBPB) range for ide-cel is between $192,000-$265,000 per dose, which would require a 37-54% discount off the treatment’s recently announced wholesale acquisition cost (WAC) of $419,500.”
> “Assuming the list price ($419,500), only 43% of the eligible patients could be treated within five years (assuming 20% uptake each year), before crossing the ICER budget impact threshold of $819 million per year.”

Source: [ICER multiple myeloma final evidence report (2021)](https://icer.org/wp-content/uploads/2020/10/ICER_Multiple-Myeloma_Final-Report_Unredacted_112222.pdf)

<a id="topic-4.1-18"></a>

### Medicare inpatient payment for CAR-T cell therapy: MS-DRG 018 relative weight methodology, FY 2027 final rule

> “In the FY 2021 IPPS/LTCH PPS final rule (85 FR 58451 through 58453), we created MS-DRG 018 for cases that include procedures describing CAR T-cell therapies.”
> “Applying this finalized methodology, based on the March 2026 update of the FY 2025 MedPAR file used for this final rule, we estimated that the average costs of cases assigned to MS-DRG 018 that are identified as clinical trial cases ($64,963) were 16 percent of the average costs of the cases assigned to MS-DRG 018 that are identified as nonclinical trial cases ($410,125).”
> “A commenter cautioned that the base payment rate for MS-DRG 018 remains insufficient to cover the actual costs of CAR T-cell and other cellular immunotherapies, raising concerns about long-term Medicare beneficiary access.”

Source: [Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026)](https://www.federalregister.gov/documents/2026/08/04/2026-15833/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-ipps-and)

<a id="topic-4.1-19"></a>

### Analyst revenue forecast for Descartes-08, December 2024

> “The revenue for Descartes-08 is expected to reach an annual total of $201 mn by 2039 in the US based off GlobalData’s Expiry Model.”

Source: [Pharmaceutical Technology Descartes-08 net present value page (2024)](https://www.pharmaceutical-technology.com/data-insights/descartes-08-cartesian-therapeutics-net-present-value/)

<a id="topic-4.1-20"></a>

### Company slide: AChR antibody-positive share and basis of the U.S. market estimate

| Item on the slide | Quoted text |
| --- | --- |
| Share of the estimated U.S. patient population with AChR antibodies | “~85%” |
| Reference cited for that share | “Lazaridis et al., 2020” |
| Basis stated for the U.S. potential addressable market | “Company internal projections, inclusive of opportunity to retreat patients” |

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-4.1-21"></a>

### Vyvgart wholesale acquisition cost per vial, September 2025

| Product and presentation | Wholesale acquisition cost | Price per mg | Vials per dose |
| --- | --- | --- | --- |
| VYVGART (efgartigimod alfa-fcab) 400 mg in 20 mL single-dose vial | “$6,314.19” | “$15.79/mg” | “2 or 3 vials per dose (weight based)” |

Source: [argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_WAC_Disclosure_for_Colorado_HCPs.pdf)

> “Pricing as of September 30, 2025. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers.”

Source: [argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_WAC_Disclosure_for_Colorado_HCPs.pdf)

<a id="topic-4.1-22"></a>

### Vyvgart Hytrulo wholesale acquisition cost per vial and prefilled syringe, October 2026

| Product and presentation | Wholesale acquisition cost | Price per mg | Units per dose |
| --- | --- | --- | --- |
| VYVGART Hytrulo single-dose vial, 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase | “$16,410.23” | “$16.28/mg” | “1 vial per dose” |
| VYVGART Hytrulo single-dose prefilled syringe, 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase | “$17,066.64” | “$17.07/mg” | “1 prefill syringe per dose” |

Source: [argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_Hytrulo_WAC_Disclosure_for_Colorado_HCPs.pdf)

> “Pricing as of October 1, 2026.”

Source: [argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026)](https://argenx.com/content/dam/argenx-corp/media-documents/regulations/VYVGART_Hytrulo_WAC_Disclosure_for_Colorado_HCPs.pdf)

<a id="topic-4.1-23"></a>

### Rystiggo list price per mL, December 2025

> “The list price1 of RYSTIGGO is $3,155.37 per mL,2 but the amount you pay will largely depending on your health plan coverage.”
> “AnalySource powered by First Data Bank accessed on December 2025. List price is also referred to as wholesale acquisition cost or WAC. WAC is the price at which UCB sells its products to wholesalers. Rystiggo is dosed in cycles. A cycle consists of 1 subcutaneous infusion given weekly for 6 weeks. The volume of RYSTIGGO given in the infusion varies based on the patient’s weight.”

Source: [UCB RYSTIGGO pricing information (2025)](https://www.ucb-usa.com/Sustainability/Affordability/RYSTIGGO-Pricing-Info)

<a id="topic-4.1-24"></a>

### Zilbrysq list price per 23.0 mg syringe, January 2026

> “The dose, and by extension the price, depends on how the patient’s weight aligns with the three ZILBRYSQ weight bands and corresponding syringes (16.6 mg, 23.0 mg, and 32.4 mg). The list price1 of ZILBRYSQ is $1,1164.21 per 23.0 mg syringe2, but the amount you pay will largely depend on your prescription drug coverage and will vary based on your weight.”
> “AnalySource powered by First Data Bank as of January 2026. List price is also referred to as wholesale acquisition cost or WAC.”
> “AnalySource as of January 2026, based on ZILBRYSQ 23.0 mg (0.574 mL) for patients weighing ≥56 kg to <77 kg.”

Source: [UCB ZILBRYSQ pricing information (2026)](https://www.ucb-usa.com/Sustainability/Affordability/ZILBRYSQ-Pricing-Info)

<a id="topic-4.1-25"></a>

### Imaavy list price per vial at approval, April 2025

> “J&J has set a list price of $12,480 per vial for its drug, saying that it is "competitively priced" compared to the other FcRn blockers, but hasn't yet revealed a launch date.”

Source: [pharmaphorum Imaavy approval article (2025)](https://pharmaphorum.com/news/jjs-swiss-army-knife-drug-gets-first-fda-approval)

<a id="topic-4.1-26"></a>

### Soliris and eculizumab biosimilar prices per vial, April 2025

> “The cost for Soliris intravenous solution is $6,523 for a single-dose vial.”
> “The price of Bkemv (eculizumab-aeeb), the first Soliris biosimilar to be approved, is $5,870.70 for a single-dose vial, about 10% below Soliris’ price.”
> “Epysqli has launched a price of $4,566.00 for a single dose, which is a 30% discount off the wholesale acquisition cost of Soliris.”

Source: [Managed Healthcare Executive eculizumab biosimilars article (2025)](https://www.managedhealthcareexecutive.com/view/bkemv-and-epysqli-two-biosimilars-of-soliris-are-now-available)

<a id="topic-4.1-27"></a>

### Uplizna wholesale acquisition cost per dose, April 2025

> “It has a wholesale acquisition cost of $140,248.50 per dose (3 vials). After two initial loading doses, patients receive Uplizna infusions every six months.”

Source: [Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025)](https://www.managedhealthcareexecutive.com/view/fda-approves-uplizna-for-chronic-inflammatory-condition-igg4-rd)

<a id="topic-4.1-28"></a>

### Annual cost of weight-based biologics by body weight: U.S. patients with myasthenia gravis

> “Patients from the Optum database (N = 5,033) had mean body weight = 86.6 kg (standard deviation [SD] = 23.1 kg) and median weight = 83.7 kg (interquartile range [IQR] 70.3-99.9 kg).”
> “In each cohort, most patients weighed ≥80 kg (58.0% Optum, 66.2% PSP).”
> “The annual cost of health-care-provider-administered treatment for patients with gMG was estimated at $223,272-$648,960 depending on drug and body weight; annual cost was highest for patients who weighed >80 kg (up to $648,960 versus up to $467,044 for patients who weighed <80 kg).”

Source: [Tse et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41422493/)

<a id="topic-4.1-29"></a>

### Medicare Part D payment per claim for immune-mediated neurologic therapies including eculizumab and inebilizumab, 2013 to 2022

> “Between 2013 and 2022, 63 unique drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune-mediated neurologic disorders (eg, autoimmune encephalitis, myasthenia gravis) accounted for 6 526 278 claims and contributed $35 billion in Medicare drug expenditures.”
> “In 2013, azathioprine had the lowest mean (SD) payment per claim ($36.36 [$29.08]), with immunoglobulins having the highest ($8606.86 [$1121.33]); by 2022, methotrexate was the least costly ($37.35 [$36.71]), with inebilizumab and eculizumab being the most costly ($38 993.14 [$8016.72]).”

Source: [Wong et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12538365/)

<a id="topic-4.1-30"></a>

### ICER budget impact model: diagnosis assumption, annual uptake, and initial market shares

> “Based on methods reported within a CADTH Common Drug Review report of eculizumab in gMG, we assumed that 100% of these gMG patients would be diagnosed.”
> “For the purposes of this analysis, 20% of these 46,870 patients initiated new efgartigimod treatment in each of the five years, resulting in 9,374 additional patients treated each year.”
> “These analyses suggested an initial modeled market share of 2.27% by patient volume for eculizumab, with the remaining 97.73% of initial market share by patient volume attributed to conventional therapies.”

Source: [ICER (2021)](https://icer.org/wp-content/uploads/2021/03/ICER_Myasthenia-Gravis_Final-Report_102021-1.pdf)

<a id="topic-4.1-31"></a>

### Proportion with refractory generalized disease: MGFA Patient Registry, United States

> “These people are classified as having treatment-refractory gMG, with prevalence estimates ranging from 5% to 15%.”
> “Overall, 782 participants met the inclusion criteria and were enrolled in the study. Based on the results of the enrollment survey, 49 participants (6%) had refractory gMG. Based on the results from all surveys, 581 participants (74%) were classified as nonrefractory and 201 (26%) as ever-refractory.”

Source: [Harris et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447171/)

<a id="topic-4.1-32"></a>

### Use of complement C5 inhibitors, FcRn blockers, and other treatments across successive treatment episodes: U.S. Komodo claims, 2017 to 2025

> “Adults with gMG were identified from Komodo Research Data (January 1, 2017-February 28, 2025).”
> “A total of 8759 patients were included (mean age: 61.5 years; 48.7% female; mean follow-up: 36.5 months). From the first (n = 7986) to fifth (n = 3340) treatment episode, AChEi use declined (80.3→57.6%), systemic corticosteroid use was consistent (49.0→63.0%), and use increased for non-steroidal immunosuppressants (12.7→40.2%), immunoglobulin (6.1→14.5%), rituximab (0.3→2.1%), C5i (0.3→3.4%), and FcRn blockers (0.3→3.8%).”

Source: [Grover et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42839213/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
